ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Sosman on Immunotherapy in Melanoma and Renal Cancer

Jeffrey A. Sosman, MD
Published: Wednesday, Aug 28, 2013

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Sosman says that though response rates to interferon and interleukin 2 are low, these responses are long-lasting. In this scenario, Sosman believes, the patient’s immune response is gaining memory.

Patients with renal cancer that have been treated with interleukin 2 and have gone into a complete remission are less likely to relapse compared with a patient who has been free of disease after a nephrectomy, Sosman says.

The best example of the change in immune response memory, Sosman says, is seen in patients with melanoma who develop vitiligo after responding to treatment. Those responses remain consistent, suggesting that the memory has been induced.

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Sosman says that though response rates to interferon and interleukin 2 are low, these responses are long-lasting. In this scenario, Sosman believes, the patient’s immune response is gaining memory.

Patients with renal cancer that have been treated with interleukin 2 and have gone into a complete remission are less likely to relapse compared with a patient who has been free of disease after a nephrectomy, Sosman says.

The best example of the change in immune response memory, Sosman says, is seen in patients with melanoma who develop vitiligo after responding to treatment. Those responses remain consistent, suggesting that the memory has been induced.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x